WO2023017484 - CYTOTOXICITY TARGETING CHIMERAS
National phase entry:
Publication Number
WO/2023/017484
Publication Date
16.02.2023
International Application No.
PCT/IB2022/057562
International Filing Date
12.08.2022
Title **
[English]
CYTOTOXICITY TARGETING CHIMERAS
[French]
CHIMÈRES CIBLANT LA CYTOTOXICITÉ
Applicants **
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Inventors
CHEN, Peiling
DARCY, Michael Gerard
DODSON, Jason W.
KNAPP-REED, Beth A.
LEACH, Craig
LI, Yuehu
MARCUS, Andrew Peter
MARINO, JR., Joseph Paul
OPLINGER, Jeffrey Alan
PHELAN, James P.
SENDER, Matthew Robert
TURUNEN, Brandon
YE, Guosen
ZHANG, Cunyu
JEONG, Jae U.
Priority Data
63/233,144
13.08.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 8566 | |
| EPO | Filing, Examination, Granting | 39576 | |
| Japan | Filing, Examination, Granting | 3143 | |
| South Korea | Filing, Examination, Granting | 4083 | |
| USA | Filing, Examination, Granting | 14340 |
Total:
69,708
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, autoimmune diseases, viral infection, or bacterial infection.[French]
La présente invention concerne des molécules hétérobifonctionnelles, appelées chimères ciblant la cytotoxicité (CyTaCs) ou des molécules de recrutement d'anticorps (ARM) qui sont capables de se lier simultanément à une protéine de surface cellulaire cible ainsi qu'à une protéine d'anticorps exogène. La présente invention concerne également des agents capables de se lier à un récepteur sur une surface d'une cellule pathogène et d'induire la déplétion de la cellule pathogène chez un sujet pour une utilisation dans le traitement du cancer, de maladies inflammatoires, de maladies auto-immunes, d'une infection virale ou d'une infection bactérienne.